Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 in an Outpatient Environment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03374917
Recruitment Status : Completed
First Posted : December 15, 2017
Last Update Posted : March 13, 2019
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of 4 weeks of continuous infusion with ABBV-951 in adult subjects with Parkinson's Disease (PD).

Condition or disease Intervention/treatment Phase
Parkinson's Disease (PD) Drug: ABBV-951 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Study in Subjects With Parkinson's Disease to Evaluate the Safety and Tolerability of Titration and Continuous Subcutaneous Infusion of ABBV-951 for up to 4 Weeks in an Outpatient Environment
Actual Study Start Date : April 18, 2018
Actual Primary Completion Date : March 4, 2019
Actual Study Completion Date : March 4, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: ABBV-951
ABBV-951 administered by continuous subcutaneous infusion (CSCI) for 4 weeks.
Drug: ABBV-951
powder for solution

Primary Outcome Measures :
  1. Percentage of Participants with Infusion Site Reactions [ Time Frame: 28 Days ]
    Local tolerability (infusion site evaluation) was assessed using the Infusion Site Assessment 2-part rating scale.

  2. Number of Participants with Adverse Events [ Time Frame: From first dose of study drug to 30 days after last dose of study drug (up to 2 months) ]
    Treatment emergent adverse events defined as any adverse event from the time of study drug administration until 30 days after discontinuation of study drug.

  3. Percentage of Participants with Markedly Abnormal Vital Signs Values [ Time Frame: 28 days ]
    Vital signs will be collected both supine and standing.

  4. Columbia-Suicide Severity Rating Scale (C-SSRS) [ Time Frame: 28 days ]
    The C-SSRS is an instrument designed to assess suicidal behavior and ideation.

  5. Percentage of Participants with Potentially Clinically Significant Laboratory Values [ Time Frame: 28 days ]
    Blood samples for serum chemistry tests will be collected following a minimum 8-hour fast.

  6. Percentage of Participants with Potentially Clinically Significant Electrocardiogram (ECG) Results [ Time Frame: 28 days ]
    A 12-lead ECG will be performed after the participant has been supine for at least 5 minutes.

Secondary Outcome Measures :
  1. Plasma Concentrations of Levodopa [ Time Frame: Days 1, 7, 14, 21, and 28 ]
    Blood samples for pharmacokinetic assessment will be collected twice at each visit.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   30 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject with a diagnosis of definite idiopathic Parkinson's disease (PD) that is levodopa-responsive according to the United Kingdom Parkinson's Disease Society Brain Bank Criteria.
  • Subject must be taking an optimized and stable regimen of oral medications for PD, which has remained stable and unchanged for at least 30 days before enrollment in this study.
  • Subject is judged inadequately controlled on current therapy in the opinion of the Investigator and must experience a minimum of 2.5 hours of "off" time per day prior to Enrollment.
  • Subjects with a MMSE score greater than or equal to 24 and considered by the Investigator to not have dementia.

Exclusion Criteria:

  • Subjects with clinically significant electrocardiogram (ECG) values.
  • History of significant skin conditions or disorders that in the Investigator's opinion would interfere with the infusion of the study drug or could interfere with study assessments.
  • Receipt of an investigational product within at least 6 weeks prior to study drug administration.
  • Subjects with moderate to severe kidney disease.
  • Consideration by the investigator for any reason that the subject is an unsuitable candidate to receive ABBV-951.
  • Patient/caregiver that cannot demonstrate proper use of the devices (drug pump and wearable device) will not be allowed to participate.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03374917

Layout table for location information
United States, Arizona
Banner Sun Health Res Inst /ID# 165840
Sun City, Arizona, United States, 85351
United States, California
Loma Linda University /ID# 165592
Loma Linda, California, United States, 92354
Univ CA, Irvine Med Ctr /ID# 165594
Orange, California, United States, 92868
United States, Florida
Compass Research /ID# 167329
Orlando, Florida, United States, 32806
United States, Kansas
Univ Kansas Med Ctr /ID# 166280
Kansas City, Kansas, United States, 66160
United States, Kentucky
University of Kentucky Chandler Medical Center /ID# 164407
Lexington, Kentucky, United States, 40536
University of Louisville /ID# 164997
Louisville, Kentucky, United States, 40202
United States, Missouri
Washington University-School of Medicine /ID# 164412
Saint Louis, Missouri, United States, 63110
United States, New York
NYU Langone Medical Center /ID# 164924
New York, New York, United States, 10016-6402
United States, Ohio
University of Cincinnati /ID# 165142
Cincinnati, Ohio, United States, 45267-0585
Cleveland Clinic Foundation /ID# 164413
Cleveland, Ohio, United States, 44195
United States, Texas
Neurology Consultants of Dallas /ID# 167116
Dallas, Texas, United States, 75251-3831
Sponsors and Collaborators
Layout table for investigator information
Study Director: AbbVie Inc. AbbVie
Layout table for additonal information
Responsible Party: AbbVie Identifier: NCT03374917    
Other Study ID Numbers: M15-739
First Posted: December 15, 2017    Key Record Dates
Last Update Posted: March 13, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by AbbVie:
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases